Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies, 1st Edition (Hardback) book cover

Pharmaceutical Biocatalysis

Important Enzymes, Novel Targets, and Therapies, 1st Edition

Edited by Peter Grunwald

Jenny Stanford Publishing

500 pages

Purchasing Options:$ = USD
Hardback: 9789814877138
pub: 2020-07-31
SAVE ~$49.99
Available for pre-order. Item will ship after 31st July 2020
$249.95
$199.96
x


FREE Standard Shipping!

Description

This volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, β-Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.

Table of Contents

Lipase-Mediated Biocatalysis as a Greener and Sustainable Choice for Pharmaceutical Processes

Monika Sharma, Tanya Bajaj, and Rohit Sharma

Phosphodiesterases

Moritz Helmstädter, Manfred Schubert-Zsilavecz

Human DOPA Decarboxylase: Catalysis and Involvement in Pharmacological Treatments for Parkinson's Disease and Aromatic Amino Acid Decarboxylase Deficiency

Mariarita Bertoldi and Giada Rossignoli

Advancing Phospholipase D Enzymes as Diverse Drug Targets

Hortensia Gomes Leal and Kimberly A. Stieglitz

IDH1 and IDH2 Mutations as Novel Therapeutic Targets in Acute Myeloid Leukemia (AML): Current Perspectives

Angelo Paci et al.

Enzymes for Prodrug-Activation in Cancer Treatment and Gene Therapies

Peter Grunwald

Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer

Mohammad Hojjat-Farsangi and Reza Khamisipour

β-Lactams and Related Compounds as Antibacterials and β-Lactamase Inhibitors

Ulrike Holzgrabe and Jens Schmitz

Non-Vitamin K Oral Anticoagulants (NOACs): New Options

Susanne Alban

Molecular Mechanisms for Statin Pleiotropy and Possible Clinical Relevance in Cardiovascular Disease

J. K. Liao

Lysosomal Storage Disorders and Enzyme Replacement Therapy

Peter Grunwald

About the Editor

Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001.

About the Series

Jenny Stanford Series on Biocatalysis

Learn more…

Subject Categories

BISAC Subject Codes/Headings:
MED009000
MEDICAL / Biotechnology
MED072000
MEDICAL / Pharmacy
SCI010000
SCIENCE / Biotechnology
SCI013000
SCIENCE / Chemistry / General
SCI013060
SCIENCE / Chemistry / Industrial & Technical
SCI086000
SCIENCE / Life Sciences / General